ClinicalTrials.gg
Status unknownNCT05104918VENUSUpdated Nov 18, 2021

Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities

A Phase 3 interventional study of Vortioxetine and Venlafaxine in Major Depressive Disorder, sponsored by Scotmann Pharmaceuticals. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by Scotmann Pharmaceuticals · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Planned enrollment
19th of 54
500 · median 413
Started
2022
with 1 other
Phase 3
31 of 54
1 open now
Registered
52nd of 54
by date

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 19th largest by planned enrollment, is one of 2 that started in 2022, is one of 31 in phase 3, and was the 52nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To the best of the knowledge of the Principal Investigators, there was no randomised controlled trial to assess the potential cognitive improvement seen with Vortioxetine, in comparison with some other most commonly used SNRI, when used as directed for the treatment of Major Depressive Disorders. As such the outcome of this trial will provide evidence to assess this claim in the Pakistani population and determine the clinical efficacy when compared to some other commonly used anti-depressants. This would be the first randomized trial dedicated for this assessment in the region with an active control of one of the most commonly used Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs) in Pakistan for the treatment of depression, Venlafaxine. It can be utilized as an alternative to MDD treatment options, especially where the focus is on improving the cognitive abilities of the patients.

Read the detailed description

What is Known?

Major Depressive Disorder (MDD) is a distressing and highly prevalent condition which affects the individual's physical, emotional and cognitive well-being, making it one of the leading causes of disability worldwide.

Rationale:

Among the other symptoms, cognitive dysfunctions are one of the major impacts of this disorder and sometimes even overshadow the depressive symptoms2. Disturbances in cognitive functions affect a person's performance in life and work, affecting their concentration, focus, memory, planning, and decision making. Moreover, lack of sleep and dominant-negative thoughts associated with depression also make the cognitive ability worse.

Literature review has consistently demonstrated the negative impact on cognitive abilities affecting the productivity and functioning of individuals with MDD, despite the wide variety of study designs or locations. Cognitive dysfunctions is one of the most common effects reported throughout these studies.

Research gap identified:

Despite the repeated emphasis given in literature indicating the pivotal importance of cognitive abilities on the daily and professional working of humans, this is one domain that is very rarely studied separately in studies.

Relevance, importance, and applicability:

On September 30, 2013, the Food and Drug Administration approved vortioxetine for the treatment of adults with MDD. Vortioxetine's precise mechanism of action is unknown. It is hypothesized that vortioxetine works via blockade of serotonin reuptake; however, vortioxetine is pharmacologically different than other SSRIs because it also works by direct modulation of various serotonin receptors8,9. Chronic therapy with early approved antidepressants causes desensitization of 5-hydroxytryptamine (5-HT1A) on the presynaptic neuron, thereby creating a negative feedback loop and possibly reducing their antidepressive effects. Vortioxetine is an agonist of 5-HT1A on the presynaptic neuron, which can accelerate the antidepressant effects, similar to pindolol, and incorporate serotonin transporter (SERT) blockade10. This molecule acts as an antagonist, agonist, and partial agonist of multiple serotonin receptors and is designed to help reduce depressive symptoms for treatment and maintain response.

Vortioxetine has shown clinically significant results in Major Depressive Disorders (MDD), and possible positive effects on the cognitive abilities of the participants were noted in a few other studies with clinically significant improvement reported. An analysis by Baune et. al showed that Vortioxetine was the only anti-depressant that improved cognitive abilities. Many other studies have backed up this finding of Vortioxetine as an anti-depressant improving the cognitive functions of patients with MDD when taken as directed.

To the best of the knowledge of Principal Investigators, there was no local study done to assess the potential cognitive improvement seen with Vortioxetine when used as directed for the treatment of Major Depressive Disorders.

Purpose of this study:

As such the purpose of this trial is to provide evidence to assess this claim in the Pakistani population. This would be the first randomized trial dedicated for this assessment in the region with active control of one of the most commonly used Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs) in Pakistan for the treatment of depression, Venlafaxine.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years
  2. Diagnosis of recurrent MDD* > 3 months
  3. >26 score of MADRS
  4. Participant is a permanent resident of Rawalpindi/Islamabad so that follow up is easy

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 or >65 years
  2. Presence of any other psychiatric disorders (other than MDD)
  3. Presence of any organic causes of depression like drug abuse, hypothyroidism, anemia, Cushing syndrome) (Attach reports**)
  4. Any physical, cognitive or language disability to perform the cognitive tests
  5. Risk of suicide
  6. Resistant to previous treatments with either of the interventions (Vortioxetine or Venlafaxine)
  7. DSST score >70 at baseline visit

    • According to (DSM-IV-TR) ** Lab tests:
  1. Urine drug test for drug abuse 2. Serum TSH to exclude Hypothyroidism 3. Serum to exclude Anaemia 4. Serum Cortisol to exclude Cushing syndrome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Vorscot Arm

    Vortioxetine 10 mg

    Drug: Vortioxetine

  • Active comparator
    Vanlafexine Arm

    Venlafaxine 75 mg

    Drug: Venlafaxine

Interventions

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    The MADRS scoring instructions indicate that a total score ranging from 0 to 6 indicates that the patient is in the normal range (no depression), a score ranging from 7 to 19 indicates "mild depression," 20 to 34 indicates "moderate depression," a score of 35 and greater indicates "severe depression," and a total score of 60 or greater indicates "very severe depression."57 There is evidence that an improvement of two points or more on the MADRS is considered clinically relevant.

    Time frame: 8 weeks

Secondary outcomes

  1. Mini Mental State Examination (MMSE Score)

    The maximum score for the MMSE is 30. A score of 25 or higher is classed as normal. If the score is below 25, the result is usually considered to be abnormal (indicating possible cognitive impairment)

    Time frame: 8 weeks

  2. Montreal congnitive score

    Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal. In the initial study data establishing the MoCA, normal controls had an average score of 27.4, compared with 22.1 in people with mild cognitive impairment (MCI) and 16.2 in people with Alzheimer's disease.

    Time frame: 8 weeks

  3. Clinical Global Impression (CGI)

    The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.\[1\] It is a brief 3-item observer-rated scale that can be used in clinical practice as well as in researches to track symptom changes.Its 3 items assess, 1) Severity of Illness (CGI-S), 2) Global Improvement (CGI-I), and 3) Efficacy Index (CGI-E, which is a measure of treatment effect and side effects specific to drugs that were administered.

    Time frame: 8 weeks

  4. Digit symbol substitution test (DSST)

    A score of 400 or higher for the majority of DSST tests is considered passing. The minimum is 200 and the maximum is 600. A score of 400 is comparable to earning a "C" grade on a test which would be considered passing. DSST tests are pass/fail and do not affect student's GPAs.

    Time frame: 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — no plan

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2022; primary completion for Apr 2022, 2 months later.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 2 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Nov 3, 2021
StartEst.
Feb 2022
Primary completionEst.
Apr 2022
CompletionEst.
Jun 2022
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05104918
Lead sponsor
Scotmann Pharmaceuticals
Collaborators
Rawalpindi Medical College
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Feb 2022 (estimated)
Primary completion
Apr 2022 (estimated)
Completion
Jun 2022 (estimated)
Last update
Nov 18, 2021

Study contacts

Mehmood ALi
Contact
lonsa25@student.london.ac.uk
00923105666079
Muhammad Umar
Contact
info@rmur.edu.pk
051-9290755 ext. 116
Muhammad Umar
principal investigator · Rawalpindi Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion